Information Provided By:
Fly News Breaks for March 2, 2017
TXMD
Mar 2, 2017 | 09:32 EDT
After attending TherapeuticsMD's Investor Day, Stifel analyst Annabel Samimy says that the label of the company's TX-004HR drug will "likely" be "favorable." She believes that the label will attribute differentiated clinical indications to the drug, and she thinks that the drug's label may not include the Boxed Warning for estrogen products. The analyst keeps a $20 price target and a Buy rating on the shares.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.